|Over a month ago|
TD Holdings names Tianshi Yang as CFO, succeeding Wei Sun » 08:3306/1106/11/21
GLG, AIH, METX
TD Holdings (GLG),…
TD Holdings (GLG), announced that Tianshi (Stanley) Yang has been appointed as the successor to Wei Sun to serve as the CCFO and director of the company's Board of Directors, effective June 11. Wei Sun resigned from her roles in the company on June 11. Yang served as the Head of Investor Relations of Aesthetic Medical International Holdings Group Ltd. (AIH) from March 2020 to May 2021 and as the Financial Department Director of Meten EdtechX Education Group (METX) from January 2019 to February 2020.
|Over a quarter ago|
Aesthetic Medical announces resignations from board committees » 08:3603/3003/30/21
Aesthetic Medical International Holdings Group announced that Mr. Tsang Eric Chi Wai has resigned from the audit committee, the compensation committee and the nominating committee of the Company's board of directors while remaining as a director on the Board; Mr. Xue Hongwei has resigned as the chair of the Nominating Committee while remaining as a member of the Nominating Committee; and Mr. Lu Feng has resigned as the chair of the Compensation Committee while remaining as a member of the Compensation Committee and as a member of the Nominating Committee. Their resignations from these committees did not result from any disagreement with the Company. To fill the vacancies, Dr. Zhou Pengwu, the chairman of the Board, will join the Nominating Committee as its chair, and Ms. Cathy Peng, an incumbent director, will join the Audit Committee and the Nominating Committee as a member and the Compensation Committee as its chairwoman.
Fly Intel: After-Hours Movers » 18:2501/0401/04/21
JEF, BPFH, AIH, LIFE, VRAY, GBIO, FATE, NGM
Check out this evening's…
Aesthetic Medical ends bid to acquire controlling interest in Guangdong Hanfei » 16:3101/0401/04/21
Aesthetic Medical announced that the company has terminated the agreement to acquire a 51% equity interest in Guangdong Hanfei Investment Management Co., Ltd. , previously announced on July 14, 2020. The termination was a result of amicable negotiation of the parties following Hanfei's failure to meet the agreed-upon performance target largely due to the impact from the COVID-19 pandemic.
Aesthetic Medical expects revenue to gradually recover in Q4 » 06:1811/3011/30/20
The company said,…
The company said, "As China gradually recovers from the aftermath of the COVID-19 outbreak, the Company has experienced recovery in its business operations. While the duration of the COVID-19 pandemic and its negative impact to market demand and the Company's business operations still cannot be conclusively and accurately estimated at this time since there is still uncertainty for possible COVID-19 outbreak in the future, subject to any uncertainty of the development of COVID-19, the Company currently expects that its revenue will gradually recover in the fourth quarter of 2020. Such expectation reflects the current and preliminary view of the Company's management team based on the information available at the time, and may be subject to changes. The Company will continue to monitor and evaluate the development of the pandemic, and the resulting financial impact on the Company."
Aesthetic Medical reports Q3 EPS RMB0.26 vs. RMB0.12 last year » 06:1711/3011/30/20
Reports Q3 revenue…
Reports Q3 revenue RMB281.3M vs. RMB237.9M last year. Dr. Zhou Pengwu, the Chairman and CEO of the Company, commented, "Our financial results for the third quarter ended September 30, 2020 reflect our management's agility and business resilience despite the full brunt and the unpredictability brought by the COVID-19 pandemic. For the third quarter of 2020, we recorded a total number of active customers of 83,222, achieving an increase of 16.4% from 71,502 in the third quarter of 2019. At the same time, our core business initiatives were well-executed and our market share in the aesthetic medical industry was strengthened primarily through our completion of the acquisition of Guangdong Pengai Hanfei Hospital Management Co., Ltd. and our integration of the industry chain. The markets have been signaling the recovery in our business and the aesthetical medical industry, as China gradually recovers from the aftermath of COVID-19 outbreak. Customers are adapting to the new normal and gradually restoring their contained enthusiasm in consuming aesthetic medical services. In addition to allocating our resources to focus on enhancing our customer stickiness and improving our brand awareness, long-term growth and returns with an emphasis on sustainability remain our priority."
Aesthetic Medical enters strategic cooperation agreement with Chengdu Meb » 09:1210/2210/22/20
Aesthetic Medical International announces it has entered into a strategic cooperation agreement with Chengdu Meb Network Technology, a social community platform in China connecting consumers, professionals and medical institutions in the aesthetics medical industry. Pursuant to the Agreement, the Company will become a member of Meb's multi-channel network, allowing more consumers on Meb's platform to have access to the Company's services. Meb will provide various marketing services to the Company, including providing marketing trainings to the Company's staff, allowing the Company to use Meb's online promotional tools, and optimizing the operation of the Company's social media platforms.
Aesthetic Medical announces $6M share repurchase program » 09:0910/1310/13/20
Aesthetic Medical International Holdings announced that its board of directors has authorized a share repurchase program under which the Company may repurchase up to $6M worth of its American depositary shares over the next 12-month period, effective until October 12, 2021, pursuant and subject to applicable laws and the Company's securities trading policy. All factors, including, but not limited to, trading price, trading volume and general market conditions, along with the Company's working capital requirements and general business conditions shall be taken into account when determining the timing, volume and conditions of the share repurchases under the share repurchase program.
Aesthetic Medical reports Q2 diluted EPS (10c), one estimate 7c » 06:0409/2509/25/20
Reports Q2 revenue…
Reports Q2 revenue $23.6M, one estimate $21.7M.